[Low galectin-3 capacity to discriminate thyroid lesions].

Rev Invest Clin

Clínica de Tiroides, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Tlalpan, México, DF.

Published: May 2005

Unlabelled: Galectin-3 is considered useful in identifying lesions included in the term follicular tumour.

Objective: To evaluate galectin-3's power to discriminate among diverse thyroid lesions and to identify a set point of expression at which there is the least possible false positive results.

Methods: 26 follicular carcinomas and 104 assorted thyroid lesions were analysed (8 Hashimoto's thyroiditis, 18 goiter, 44 adenoma, 27 papillary carcinoma and 7 normal glands). Immunohistochemistry for galectin-3 was performed way (NCL-GAL-3, 1:100, Novocastra, UK). In a blinded manner intensity and percentage of expression were evaluated, as was its capacity to identify the previously mentioned thyroid entities with 2 x 2 tables. Minimum reactivity set point values were identified and the one which presented the least false positive cases was selected.

Results: A reaction was considered positive when 25% of the cells were marked, in which case neither the Hashimoto's thyroiditis, goiter, nor the residual tissue were positive for galectin-3. A positive galectin-3 reaction was identified in 4/44 adenomas, 5/26 follicular carcinomas and 18/27 papillary carcinomas. From a total of 53 carcinomas, 23 showed positive and 30 a negative reaction to galectin-3. Thus, galectin-3's sensitivity to discriminate between benign and malignant lesions was 94% while its specificity was 43%. When comparing follicular carcinoma with adenoma, sensibility was 19% while specificity was 91%. The positive predictive value was 56% and the negative predictive value 66%. Galectin-3 was most useful for identifying papillary thyroid carcinoma.

Conclusions: Galectin-3 has limited value to distinguish benign from malignant thyroid lesions. The reaction must be considered positive when at least 25% of cells are marked.

Download full-text PDF

Source

Publication Analysis

Top Keywords

thyroid lesions
12
set point
8
positive
8
false positive
8
follicular carcinomas
8
hashimoto's thyroiditis
8
thyroiditis goiter
8
reaction considered
8
considered positive
8
positive 25%
8

Similar Publications

A 65-year-old patient presented with recurrent, locally advanced poorly differentiated thyroid cancer despite 2 neck surgeries, and with newly diagnosed brain and skull base metastases. He was treated with palliative stereotactic radiosurgery to the brain and skull base lesions. Thereafter, as no targetable genetic alteration was identified and antiangiogenic multikinase inhibitors were deemed at high risk of hemorrhagic complications, off-label systemic therapies were considered.

View Article and Find Full Text PDF

Hyperparathyroidism-jaw tumor syndrome (HPT-JT) is a rare hereditary disorder caused by pathogenic gene variants. We report the case of a patient with HPT-JT who carried a novel germline pathogenic variant. A 27-year-old woman presented with thirst, polyuria, fatigue, constipation, and a history of fibro-osseous mandible lesions and endometrial polyps.

View Article and Find Full Text PDF

Background: Occult papillary thyroid carcinoma (PTC) refers to the PTC accidentally found due to its occult lesions. Classic, as the most common subtype of PTC, is usually considered to have a low degree of malignancy and a favorable prognosis. Currently, the American Thyroid Association Management Guidelines adopted active surveillance (AS) as an alternative to immediate surgery in some low-risk PTC patients with less than 1 cm in diameter.

View Article and Find Full Text PDF

A retrospective study was performed to determine the incidences of spontaneous findings in control laboratory New Zealand White (NZW) and Dutch Belted (DB) rabbits. Terminal body and organ weights data were also collected. A total of 2170 NZW (526 males/1644 females), 100 DB rabbits (50 animals per sex), aged 4- to 7-month-old were obtained from 158 non-clinical studies evaluated between 2013 and 2022.

View Article and Find Full Text PDF

Radiotherapeutics, clonal hematopoiesis, and risk of hematologic malignancies: The good, the bad, the ugly.

Blood Rev

January 2025

Mayo Clinic, Division of Hematology, Department of Medicine, 200 1(st) St SW, Rochester, MN 55905, United States of America. Electronic address:

While radiotherapeutics have demonstrated significant clinical benefit across multiple cancer types including thyroid cancer, neuroendocrine tumors, and prostate cancer, hematological toxicities can be frequent and challenging. It remains unknown to what extent the hematologic toxicity is driven by clonal processes that preexist and are selected for by treatment induced selection pressures. In this review, we discuss the background leading to the adoption of radiotherapeutics in the treatment of solid tumor malignancies, the risk of hematologic toxicities and myeloid neoplasms and the evidence pointing to potential precursor lesions that may predispose patients to hematologic toxicities.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!